Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar
Stock Information for PLUS THERAPEUTICS Inc.
Loading
Please wait while we load your information from QuoteMedia.